Compare AUID & OSRH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AUID | OSRH |
|---|---|---|
| Founded | 2009 | N/A |
| Country | United States | United States |
| Employees | N/A | 22 |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.4M | 17.9M |
| IPO Year | 2014 | N/A |
| Metric | AUID | OSRH |
|---|---|---|
| Price | $1.27 | $0.50 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 143.2K | ★ 15.4M |
| Earning Date | 05-12-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,040,660.00 | N/A |
| Revenue This Year | N/A | $9.30 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 130.20 | N/A |
| 52 Week Low | $0.84 | $0.38 |
| 52 Week High | $5.82 | $1.79 |
| Indicator | AUID | OSRH |
|---|---|---|
| Relative Strength Index (RSI) | 53.26 | 44.14 |
| Support Level | $1.16 | $0.42 |
| Resistance Level | $1.42 | $0.74 |
| Average True Range (ATR) | 0.11 | 0.06 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 67.92 | 6.53 |
AuthID Inc is a company engaged in ensuring cyber-savvy enterprises Know Who's Behind the Device, for every customer or employee login and transaction. Through its easy-to-integrate, patented, biometric identity platform, authID quickly and accurately verifies a user's identity, eliminating any assumption of who is behind a device and preventing cybercriminals from taking over accounts. authID combines digital onboarding, biometric password less authentication and account recovery, with a fast, accurate, user-friendly experience-delivering identity verification.
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea. The company's pipeline products include: Vaximm, Darnatein, Woori IO, and RMC.